Company
Headquarters: Chadds Ford, PA, United States
Employees: 8
CEO: Mr. Michael C. Boyd
Company | Market Cap (USD) |
---|---|
Abbott | $178.02 B |
Stryker Corporation | $126.48 B |
Boston Scientific Corporation | $112.32 B |
Medtronic | $98.95 B |
Edwards Lifesciences Corporation | $55.63 B |
Company | Market Cap (USD) |
---|---|
Lilly | $808.65 B |
Novo Nordisk | $622.07 B |
UnitedHealth Group | $450.89 B |
Johnson & Johnson | $350.63 B |
Merck | $318.75 B |
Longport, Inc. develops, manufactures, markets, and sells high resolution ultrasound imaging systems primarily in the United States. It offers EPISCAN I-200, a high frequency ultrasound imaging system that utilizes ultrasound at frequencies between 20 and 50MHz to image the skin and underlying soft tissue. The company's products are used in wound assessment, wound prevention, clinical dermatology, and aesthetics/plastics, as well as in various other applications, including burn assessment, superficial musculoskeletal imaging, and veterinary applications. It also exports its products. The company was founded in 1993 and is based in Chadds Ford, Pennsylvania.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Longport, Inc. has the following listings and related stock indices.
Stock: OTC: LPTI wb_incandescent